Next Article in Journal
Growth, Structure, and Photocatalytic Properties of Hierarchical V2O5–TiO2 Nanotube Arrays Obtained from the One-step Anodic Oxidation of Ti–V Alloys
Previous Article in Journal
Experimental and Theoretical Reduction Potentials of Some Biologically Active ortho-Carbonyl para-Quinones
Previous Article in Special Issue
What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma?
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Molecules 2017, 22(4), 563;

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease

Dubowitz Neuromuscular Centre, Molecular Neurosciences Section, Developmental Neuroscience Programme, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK
MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London WC1N 3BG, UK
UOL Medical Genetics, University of Ferrara, Ferrara 44121, Italy
Authors to whom correspondence should be addressed.
Academic Editor: Wai Shiu Fred Wong
Received: 21 December 2016 / Revised: 28 February 2017 / Accepted: 14 March 2017 / Published: 5 April 2017
(This article belongs to the Special Issue Nucleic Acid-based Drug)
Full-Text   |   PDF [1915 KB, uploaded 5 April 2017]   |  


Neuromuscular disorders such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy are neurodegenerative genetic diseases characterized primarily by muscle weakness and wasting. Until recently there were no effective therapies for these conditions, but antisense oligonucleotides, a new class of synthetic single stranded molecules of nucleic acids, have demonstrated promising experimental results and are at different stages of regulatory approval. The antisense oligonucleotides can modulate the protein expression via targeting hnRNAs or mRNAs and inducing interference with splicing, mRNA degradation, or arrest of translation, finally, resulting in rescue or reduction of the target protein expression. Different classes of antisense oligonucleotides are being tested in several clinical trials, and limitations of their clinical efficacy and toxicity have been reported for some of these compounds, while more encouraging results have supported the development of others. New generation antisense oligonucleotides are also being tested in preclinical models together with specific delivery systems that could allow some of the limitations of current antisense oligonucleotides to be overcome, to improve the cell penetration, to achieve more robust target engagement, and hopefully also be associated with acceptable toxicity. This review article describes the chemical properties and molecular mechanisms of action of the antisense oligonucleotides and the therapeutic implications these compounds have in neuromuscular diseases. Current strategies and carrier systems available for the oligonucleotides delivery will be also described to provide an overview on the past, present and future of these appealing molecules. View Full-Text
Keywords: Duchenne Muscular Dystrophy; Spinal Muscular Atrophy; antisense oligonucleotides; clinical trials; oligonucleotides delivery Duchenne Muscular Dystrophy; Spinal Muscular Atrophy; antisense oligonucleotides; clinical trials; oligonucleotides delivery

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Sardone, V.; Zhou, H.; Muntoni, F.; Ferlini, A.; Falzarano, M.S. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules 2017, 22, 563.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top